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DNA-based cancer vaccines represent an attractive strategy for inducing immunity to tumor associated antigens (TAAs) in cancer
patients. The demonstration that the delivery of a recombinant plasmid encoding epitopes can lead to epitope production,
processing, and presentation to CD8+ T-lymphocytes, and the advantage of using a single DNA construct encoding multiple
epitopes of one or more TAAs to elicit a broad spectrum of cytotoxic T-lymphocytes has encouraged the development of a
variety of strategies aimed at increasing immunogenicity of TAA polyepitope DNA-based vaccines. The polyepitope DNA-based
cancer vaccine approach can (a) circumvent the variability of peptide presentation by tumor cells, (b) allow the introduction
in the plasmid construct of multiple immunogenic epitopes including heteroclitic epitope versions, and (c) permit to enroll
patients with diﬀerent major histocompatibility complex (MHC) haplotypes. This review will discuss the rationale for using the
TAA polyepitope DNA-based vaccination strategy and recent results corroborating the usefulness of DNA encoding polyepitope
vaccines as a potential tool for cancer therapy.
1.Introduction
The discovery that the abnormal expression of a given self
tumor-associated antigen (TAA), resulting from overexpres-
sion, conformational changes, or posttranslational modiﬁ-
cations, can overcome self-tolerance and induce immune
responses to cancer cells has grown the idea that the immune
system can ﬁght against cancer [1–5]. The identiﬁcation and
molecular characterization of TAAs provided the basis for
the development of cancer vaccines targeting TAAs [6]. Full-
length recombinant forms of TAAs have been administered
to animal models and then to cancer patients, with the aim
of inducing induce a systemic immune response to the TAA
that may result in the killing of cancer cells in the recipient
[7].
The use of epitope-based cancer vaccines as the most
speciﬁcmethodtotriggerTcellsagainstcancercellshasbeen
ﬁrst investigated by employing peptide-based vaccination.
This approach was further supported by the knowledge
that: (a) within a given antigen, a T cell recognizes only a
single epitope (peptide) bound to major histocompatibility
complex (MHC) proteins; (b) MHC class I and class II
molecules bind to short peptides of 8–10 and 13–20 amino
acids, respectively; (c) CD4+ and CD8+ T cells are activated
by MHC classI- and class II-presented peptides, respectively;
(d)TAApeptidesareexposedoncancercells[8–10].Peptide-
based cancer vaccines display unique features: they are
relatively easy to prepare for clinical use, have minimal
toxicity, and can include multiple peptides in order to
bypass tumor heterogeneity and immune escape. Further,
the induced T cell-response can be easily analyzed. On the
other hand, the use of peptide-based cancer vaccines might
display several drawbacks: (a) T-cell epitope restriction to a
particular MHC haplotype, (b) inadequate activation of the
innate immune system, (c) the need of adjuvants to trigger
immune responses to subdominant or weakly immunogenic
peptides, and (d) possible immunoselection of epitope-loss
variants after single peptide vaccinations [8–10].2 Journal of Biomedicine and Biotechnology
2. The Choice of the TAAEpitope/s:
A Lesson fromPeptide-BasedClinicalTrials
in Cancer Patients
2.1. Promise and Limits of Peptide-Based Single Epitope
Vaccination. Most of the knowledge on the employment of
TAA single epitope-based cancer vaccines was obtained from
single peptide-based vaccination trials in cancer patients.
Recent studies are reported below. These studies revealed
fundamentalconceptsontheinvivoimmunogenicityofTAA
peptides in cancer patients.
2.1.1. Single Epitope Peptide-Vaccination. Many single epi-
tope peptide-based cancer vaccines have been developed in
preclinical as well as in clinical settings [8–16]. Peptides
from melanoma antigens were the ﬁrst to be employed
as immunogens in phase I and II clinical trials for the
treatment of melanoma patients [11]. It should be pointed
out that the ﬁrst clinical trials were conducted in melanoma
patients since melanoma is the human (nonvirally induced)
most immunogenic cancer. Then, similar trials have been
conducted for less immunogenic cancers. Rosenberg et al.,
by investigating the reactivity of PBMCs from 8 of the 9
melanoma patients immunized with the native g209–217
form of the gp100 melanoma-associated antigen, showed
that only 2 of 8 patients had reproducible evidence of
immunization to the native g209–217 peptide and only one
patient experienced an objective cancer regression that lasted
4 months [11]. It was also demonstrated that the in vivo
administration of the MART-1(27–35) peptide from the
melanoma-associated antigen could safely augment Cyto-
toxic T Lymphocytes (CTL) reactivity against epitopes com-
monly expressed by melanoma cells in melanoma patients.
However, despite the enhancement of CTL reactivity, tumor
regression was not achieved [13]. Conversely, it was found
that among the 25 patients who received 3 subcutaneous
injections of the MAGE-3.A1 peptide, 7 displayed signiﬁcant
tumor regression [14]. Intradermal vaccination of patients
with metastatic NY-ESO-1-expressing cancers with 3 HLA-
A2-binding NY-ESO-1 peptides was shown to elicit immune
responses as well [15] .R e m a r k a b l y ,1 0o f2 2p a t i e n t s
with high-risk, resected, stages IIB, III, and IV melanoma,
immunizedwithanimmunodominant9-aminoacidpeptide
derived from the MART-1 tumor antigen (AAGIGILTV),
developed an immune response that was associated with a
prolonged time to relapse [16].
Based on these clinical trials, peptides derived from
other TAAs were employed to immunize patients aﬀected
by diﬀerent types of cancer [17–22]. For instance, early-
staged breast cancer patients provided evidence for the
induction of intra- and interantigenic epitope spreading
afterminimalessentialHER-2/neuepitope(E75)vaccination
[17]. Disis et al. showed that the majority of patients
withHER-2/neu-overexpressing breast,ovarian, ornonsmall
cell lung cancers developed immunity to both HER-2/neu
peptides and protein when immunized with subdominant
peptide epitopes derived from HER-2/neu [18]. Patients
with advanced cancer showing an immune response to
the mutant ras 17-mer peptides used as vaccines had
prolonged survival from the start of treatment compared to
nonresponders [19]. Yamamoto’s group demonstrated that
after vaccination with a 100-mer MUC1 peptide consisting
of the extracellular tandem repeat domain, 7 out of 8
patients with advanced pancreatic and bile duct cancers
had progressive disease while 1 out of 8 had stable disease
with a tendency for increased circulating anti-MUC1 IgG
antibodies [20]. Vaccination of pancreatic cancer patients
with a 100-amino acid peptide corresponding to ﬁve 20-
amino acid long repeats of the same antigen and SB-AS2
adjuvant resulted in an increased percentage of CD8+ T
cells in the peripheral blood. In addition, 2 of 15 resected
pancreatic cancer patients were alive and disease-free at
follow-up of 32 and 61 months [21]. Furthermore, phase
I/II studies demonstrated that the combined administration
of irinotecan/high-dose 5-FU/leucovorin with CAP-1, that
is, the immunodominant MHC class I HLA-A2-restricted
nonamer epitope of the carcinoembryonic antigen (CEA),
increases CAP-1-speciﬁc T cells in 47% of colorectal cancer
patients after vaccination [22].
Accordingly, in spite of the solid preclinical rationale,
singlepeptide-basedcancervaccineshavegeneratedcompar-
atively poor objective clinical responses in cancer patients.
Still, the development of novel engineered peptides and
the knowledge of the molecular mechanisms regulating
immunity to cancer cells have oﬀered new motivations for
the use of single epitope peptide-based vaccination in cancer
patients.
2.1.2. Improvement of Single Epitope Peptide Immunogenicity.
Although the discovery of immunodominant epitopes was
essential for vaccine development, the knowledge of uncon-
ventional epitopes involved in antigen immune recognition
could provide useful indications to increase immunity to
TAAs, thus leading to the development of novel cancer
vaccine strategies. A starting point in this respect was the
demonstration that although self TAAs can elicit immune
responses in cancer patients, the induced T cells response is
weak and ineﬀective [23–26]. One explanation for this event
is that thymic negative selection leads to the deletion of T cell
progenitorswhichareabletorecognizewithhighavidityself-
peptides bound to MHC molecules displayed on the surface
ofantigenpresentingcells(APCs).Yet,anindividualtolerant
to immunodominant self-epitopes can recognize unconven-
tional self-epitopes generated from nontraditional sources
of peptides/proteins and/or mechanisms of translation,
including cryptic epitopes and atypical epitopes originating
from incompletely spliced messages, mutation of a normally
noncoding intronic sequence, exon extension, ribosomal
frameshifting, initiation codon scanthrough, initiation from
non-AUG codons, and doublet decoding [23–26].
Diﬀerent approaches were investigated in order to
develop novel peptide constructs able to increase peptide
immunogenicity or to increase the TCR repertoire available
for immune recognition of tumors. To improve epitope
immunogenicity, two general strategies have been employed.
The ﬁrst aims at increasing peptide aﬃnity to MHC,
essentially class I molecules. Indeed, an enhanced aﬃnity
resultsinalongercomplexhalf-lifeoncellsurfacesincreasingJournal of Biomedicine and Biotechnology 3
the chance of CTL stimulation. The second strategy aims at
improving the processing/production of the epitopes. Recent
examples of epitope modiﬁcations are described below. One
methodology was based on the identiﬁcation of heteroclitic
peptides which represent altered peptide ligands (APLs)
with enhanced functional activity relative to the parental
peptide. Most studies of APLs of tumor antigens employed
amino acid exchanges at anchor residue positions of the
peptide to enhance its binding to class I MHC molecules
[10]. Notably, the lateral chain of the major anchor residues
being buried, the introduction of the most favorable residues
at these positions should not alter epitope antigenicity.
Other studies of APLs of tumor antigens employed the
introduction of aromatic amino acids at P1, P4, and P5
position, modiﬁcation of individual amino acid residues,
modiﬁcation of cysteine residues, or modiﬁcation of TCR-
interacting amino acid residues [10]. Other modiﬁcations
have been empirically discovered with the same aﬃnity
eﬀect. These modiﬁcations would not apply to all allelic
forms of MHC class I molecules. For those modiﬁcations
thathavebeenfoundtoincreaseimmunogenicityofepitopes
without increasing aﬃnity, increased interaction with TCR
remains an hypothesis.
Among diﬀerent modiﬁcations, Zaremba et al. intro-
duced a single amino acid substitutions to the CAP-1
peptide (YLSGANLNL). Whereas CAP-1 failed to generate
CTLs from normal PBMCs, the agonist peptide was able to
generate CD8+ CTL lines that recognized both the agonist
and the native CAP-1 sequences [27]. In addition, the mod-
iﬁcation of position 6 of the CAP-1 peptide from asparagine
to aspartic acid dramatically shifted the dose of peptide
resulting in maximal production of inﬂammatory cytokines
[28]. Loftus et al. identiﬁed several partial agonists or
antagonists of MART1(27–35)-reactive CTL clones derived
from tumor inﬁltrating lymphocytes (TILs) [29]. It was
also demonstrated that a singly substituted peptide derived
from the epitope MART1(27–35), containing a leucine in
position 1, acted as a superagonist by inducing speciﬁc T
cells with enhanced immunological functions in vitro [30].
Theintroductionofasingleleucinetoalaninesubstitutionat
position 2 of the Melan-A26–35 decapeptide sequence into
a recombinant vaccinia virus encoding the Melan-A26–35
minigene resulted in a strongly increased immunogenicity
in vitro and in vivo [31]. Two more immunogenic variants
of the wt p53(264–272) peptide were identiﬁed by amino
acid exchanges at positions 6 and 7 of the peptide. These
variants were capable of inducing T cells that recognized the
parental peptide from PBMCs of nonresponsive donors [32].
The HER-2.369 V2V9 variant, generated by introducing in
the wild type peptide a valine at position 2 and a valine at
the C terminus, was shown to be a more potent immunogen
than the wild-type epitope, and T cell responses activated by
this analogue were able to recognize the naturally processed
epitopeontumortargetcells.Theincreasedimmunogenicity
was associated with only a marginal increase in HLA class I
binding of the variant epitope [33].
A novel approach is based on the knowledge that self-
tolerance to immunodominant TAA epitopes might be
circumvented through the recruitment of high avidity T
cell repertoires speciﬁc for subdominant or cryptic TAA
epitopes.Onthisregard,manygroupshaveaimedatenhanc-
ing immunogenicity of nonimmunogenic low-aﬃnity HLA-
A2.1-binding peptides, by introducing a tyrosine in the ﬁrst
positionoftheaminoacidsequence(P1Y).Suchstrategywas
described for the ﬁrst time by Tourdot et al. The P1Y sub-
stitution was able to increase peptide aﬃnity of HLA-A2.1-
binding peptides without altering their antigenic speciﬁcity
[34].Onthisline,Scardinoetal.usedtheheterocliticpeptide
approach to identify six low aﬃnity, cryptic HER-2/neu,
and hTERT epitopes presented by HLA-A
∗0201. These
epitopes,intheirP1Yheterocliticform,stimulatedCTLsthat
speciﬁcally lysed HER-2/neu- or hTERT-expressing tumor
cells of various histological origins [35].
MHC class II-restricted immune responses can be
increased by targeting the peptide through the invariant
(Ii) chain-MHC class II biosynthesis pathway. The Ii chain
protein is proteolyzed leaving a peptide called CLIP inside
the peptide-binding groove of MHC class II [36]. CLIP
appears to have superagonistic properties interacting with
the T cell receptor and the MHC class II molecule at or near
the binding site for the bacterial superantigen Staphylococcal
enterotoxin B, and thus it can aﬀect MHC class II stabi-
lization, peptide antigen exchange, and antigen presentation
[37].Hessetal.investigatedwhethertheN-terminalﬂanking
region of the Ii peptide could augment the immunogenicity
of cryptic “self” TAAs. Indeed, by introducing the ﬂanking
region of the Ii peptide, one expects a very eﬃcient cut
by the cathepsins since the amino acids of these regions
are well conserved across species, insuring a very eﬃcient
ﬁnal fragmentation of the Ii before MHC class II peptide
loading. The authors demonstrated that immunogenicity of
an MHC class II-binding peptide (p1171–1185) from the
rat (c-neu) HER-2/neu oncogene was augmented by the
addition of the N-terminal segment of CLIP [37]. Similarly,
Voutsas et al. demonstrated that Ii-Key/HER-2/neu(776–
790) hybrid peptides primed higher frequencies of CD4+
T cells compared to the native peptide following active
vaccination in DR4-IE Tg mice. The hybrid peptide-induced
CD4+ T cells in turn stimulated higher HER-2/neu peptide-
speciﬁc CTL responses and resulted in tumor regression in
SCID mice xenografted with an HER-2/neu+ tumor cell
line [38]. The Ii-Key/HER-2/neu(776–790) hybrid peptides
were also shown to induce more eﬀective immunological
responses over the native peptide in lymphocyte cultures
from patients with HER-2/neu+ tumors [39]. In addition,
an Ii-Key hybrid of HER-2/neu peptide 776 to 790, when
injected in node-negative breast cancer patients expressing
varying levels of HER-2/neu, induced a potent immune
response in the absence of an immunoadjuvant [40]. Indeed,
the Ii-Key/MHC class II epitope hybrid acts on MHC class
II molecules to facilitate replacement of antigenic peptides
with the epitope tethered to the Ii-Key motif. In this way,
it greatly increases Th1 or Th2 responses to MHC class II
epitopes [41].
A novel approach to enhance immunity against a self-
HER-2/neu CTL epitope by vaccinating with xenogeneic,
altered peptide ligands was proposed by Gritzapis et al.
[42]. Two HER-2/neu-derived E75 APLs that demonstrated4 Journal of Biomedicine and Biotechnology
increasedaﬃnitiesfortheHLA-A
∗0201allelecomparedwith
wild-type E75 peptide were also developed [43]. Kobayashi
described a strategy to identify helper T-cell epitopes for
HER-2/neu that were able to trigger human T cell responses
in individuals expressing diverse HLA-DR alleles (promiscu-
ous epitopes) [44].
2.1.3. Polyepitope Delivery by Multipeptides-Based Vaccina-
tion. The rationale for the ﬁrst use of TAA polyepitope
cancer vaccines was based upon the evidence that: (a) as
compared to a single epitope-based cancer vaccine, the
injection of multiple epitopes can overcome the potential
loss of expression of a given TAA-single epitope in cancer
cells; (b) the ability to target more than one TAA can
counteracttheheterogeneousexpressionofTAAsbydiﬀerent
cancercellswithinatumor;(c)thevaccinationwithmultiple
epitopes would allow to enroll patients with diﬀerent HLAs
[9, 10]. Afterwards, multiepitopes-based cancer vaccines
were considered not only for their potential to circumvent
the variability of immunodominant peptides presentation by
tumor cells, but also because, by using engineered peptides,
they can induce the recruitment of diverse high avidity TCR
repertoiresspeciﬁcforselfTAApeptidesinvivo.Resultsfrom
recent clinical trials of polyepitope peptide-based vaccines
are reported below. A phase I/II trial was conducted to assess
thefeasibilityandtolerabilityofvaccinationwithacocktailof
11 synthetic peptides derived from several TAAs, including
prostate speciﬁc and membrane antigens, in 19 HLA-A2
positivepatientswithhormone-sensitiveprostatecarcinoma.
The result of this trial demonstrated that the multipeptide
vaccine stabilized or slowed down prostate speciﬁc antigen
(PSA) progress in 4 of 19 cases, with long-term stability
delaying androgen deprivation up to 31 months [45].
Kirkwood et al. reported the results of a randomized, multi-
institutional trial of multi-epitope peptide vaccination for
patients who failed prior therapy for metastatic unresectable
melanoma. Three HLA class I-restricted lineage antigen
epitopes were administered alone (arm A), or combined
with granulocyte-monocyte colony-stimulating factor (GM-
CSF) (arm B), or with IFN-α2b (arm C), or with both
IFN-α2b and GM-CSF (arm D). The authors showed that
immune responses to at least one melanoma antigen were
observed in 35% of patients and that 6 out of 115 patients
had objective clinical responses. Neither IFN-α2b nor GM-
CSF signiﬁcantly improved immune responses [46]. Thirty-
three of 38 patients with high-risk, resected, stage III or IV
melanoma showed an immune response after vaccination
with two tumor antigen epitope peptides derived from
gp100 (209–217) and tyrosinase (368–376) emulsiﬁed with
incomplete Freund’s adjuvant administered alone or in
combination with IL-12 [47]. In the clinical trial performed
by Slingluﬀ et al., 120 eligible patients with resected, stage
IIB to IV melanoma were vaccinated with 12MHC class I-
restrictedmelanomapeptidestostimulateCD8+Tcells,plus
an HLA-DR-restricted tetanus helper peptide to stimulate
CD4+ T cells, emulsiﬁed in incomplete Freund’s adjuvant,
with or without GM-CSF. The authors reported that high
immune response rates were achieved using this multipep-
tides vaccine, but that CD8+ and CD4+ T-cell responses
were lower when the vaccine was administered with GM-
CSF [48]. On the other hand, it was also demonstrated
that by mixing the highly immunogenic gp100:209–217
peptide and the less immunogenic tyrosinase: 368–376
peptide in the same emulsion, the elicited immune response
was altered as compared with that obtained with the same
peptides injected separately [49]. Five class I MHC-restricted
synthetic peptides derived from multiple ovarian cancer-
associated proteins plus a class II MHC-restricted synthetic
helperpeptidederivedfromtetanustoxoidproteinwereused
to immunize 9 patients with epithelial ovarian, fallopian
tube, or primary peritoneal carcinoma, who were HLA-
A1-, HLA-A2-, or HLA-A3-positive. In this clinical trial,
CD8+ T-cell responses were detected in 1 participant ex vivo
and in 8 of 9 participants (89%) after in vitro stimulation
[50]. In patients with stage IIIB or IV nonsmall-cell lung
cancer the clinical eﬃcacy, safety, and immunogenicity of
a multiepitopes vaccine consisting of 9 HLA-A2 supertype-
binding epitopes (2 native and 7 analog epitopes modiﬁed
for optimal HLA binding or T-cell receptor stimulation)
covering ﬁve TAAs including CEA, HER-2, MAGE3, and
the universal helper pan-DR epitope, formulated as a stable
emulsion with incomplete Freund’s adjuvant was evaluated.
One complete and one partial response and longer survival
in patients demonstrating an immune response to epitope
peptides were observed [51].
3.Polyepitope DNA-Based CancerVaccines:
ParametersAffecting the Immune Response
Multiepitopes-based vaccines may represent promising tools
for inducing antitumor immune responses in cancer
patients. The presence of immunodominant and unconven-
tional epitopes simultaneously delivered by a polyepitope
DNA-based vaccine can induce a multiple response by
generating diﬀerent self-reactive T cell repertoires. The
demonstration that the in vivo injection of RNA and DNA
mammalian expression vectors containing foreign genes into
mouse skeletal muscle was able to induce foreign protein
expression in muscle cells opened up the discovery of a
novel type of immunization [52]. Indeed, shortly after,
Ulmer et al. demonstrated that a plasmid DNA encoding
inﬂuenza A nucleoprotein injected into the quadriceps of
BALB/c mice resulted in the generation of nucleoprotein-
speciﬁc CTLs and protection from a subsequent challenge
with a heterologous strain of inﬂuenza A virus [53]. After
this study, a consistent number of reports demonstrated the
ability of DNA vaccines encoding tumor antigens to induce
protective immunity against cancer cell growth [52]. DNA
cancer vaccines are a type of genetic vaccines which depend
on delivery of plasmid DNA molecules encoding a whole
p r o t e i no re p i t o p eo fag i v e nT A A[ 54]. The usefulness of
DNA-based cancer vaccines has been demonstrated most
eﬀectively by targeting TAAs in mouse experimental models
[55–57]. In general, plasmid DNA encoding TAA epitope/s,
due to its content of unmethylated CG sequences, furnishes
a potent danger signal, which represents a natural adjuvant
stimulating the innate immunity. In addition, the expressionJournal of Biomedicine and Biotechnology 5
of a given DNA-encoded TAA epitope will be delivered
at the site where resident APCs can be activated resulting
in inﬂammation and enhanced antigen processation and
presentation. The in vivo synthesis permits appropriate
folding and posttranslational modiﬁcation of the encoded
protein, its prolonged expression, and its presentation with
MHC class I. Furthermore, DNA vaccines allow the delivery
of multiple epitopes and yet more than one full-length
antigen in conjunction with immunostimulatory molecules.
A supplementary feature supporting the development of
plasmid DNA-based vaccines takes account of the easy
preparation of the vaccine [55–57].
Intramuscular or skin injection is usually employed to
delivery DNA vaccines. Injected myocytes or keratinocytes
express the delivered antigen cDNA and serve as a target
for immune eﬀector cells. They can also increase the
expression of MHC class I and costimulatory molecules
[58]. However, it is believed that the obtained immune
responseuponrecombinantplasmidDNAvaccinationisdue
toindirectantigentransfertoAPCs(cross-presentation)[58]
(Figure 1). Skin APCs include immature Langherans cells
in the epidermis and mature dendritic cells in the dermis.
Although the cross-presentation process appears to support
CD4+ T-cell responses, recent evidences demonstrated that
endoplasmic reticulum-phagosome fusion deﬁnes an MHC
class I cross-presentation compartment in dendritic cells
[59].
OneoftheadvantagesofusingDNAfusiongenevaccines
is the possibility to incorporate in the same DNA construct
genes which encode for potentially adjuvant proteins which
are able to increase the innate immune response against the
given TAA. Accordingly, recombinant DNA plasmids were
generated by fusing genes encoding cytokines, chemokines,
Fc receptors, complement components, or antibodies target-
ing APCs, with the aim of increasing antigen uptake and
presentation [60].
Yet, one crucial feature in the construction of the DNA
vaccine is the ability to improve TAA presentation and
processing.Itisknownthatthoseantigenswhicharetargeted
to the endoplasmic reticulum will be able to induce the
production of antibodies, whereas the antigens targeted to
the cytosol will be delivered for proteasomal degradation
for induction of peptide-speciﬁc CD8+ T cells [58, 60].
Accordingly, a supplementary gene encoding ubiquitin can
be incorporated in the construct for induction of CTLs [59].
In a similar way, CD4+ T cell responses can be enhanced
by targeting TAA expression to the endosomal or lysosomal
compartment [61].
Diﬀerent parameters can aﬀect the immunological prop-
erties of a polyepitope vaccine: (a) the presence of a T
helper (Th) epitope, (b) the addition of spacers between
the epitopes for optimal cleavage of the epitopes by the
proteasome, (c) the design of new junctional epitopes, and
ﬁnally (d) the aﬃnity of the selected epitopes for MHC
molecules and transporters (TAPs). However, all the results
available from the literature do not allow to establish a
consensusonthepreciseroleofeachoneoftheseparameters.
If exceptions have been reported regarding the advantage
conferred by the addition of T helper epitopes or alanine
Polyepitope DNA vaccine
Keratinocyte
Myocyte
Antigen cross-presentation
Dendritic cell
CD4+
CD8+
E1 E5 E4 E2 E3
Figure 1: Polyepitope DNA-based cancer vaccines and cross-antigen
presentation. After injection of the recombinant polyepitope DNA
vaccine into myocyte or keratinocytes, antigenic materials is
transferred to dendritic cells (antigen cross-presentation).
ﬂanking sequences, at least these two actions have not been
reported to have adverse eﬀects.
Mateo et al. suggested that the immunogenicity of
peptides included in a melanoma polyepitope recombinant
vaccine was conditioned by their aﬃnity for the MHC [62].
Conversely, Ishioka et al., by employing an HIV polyepitope
DNA vaccine, showed that the aﬃnity of the epitopes for
MHC does not interfere with their capacity to induce a
CTL response [63]. On the other hand, Palmowski et al.
demonstrated that the diﬀerential MHC aﬃnity of peptides
included within a polyepitope DNA vaccine was crucial for
skewing of immune response and CTL immunodominance
[64]. Concerning the need for a Th epitope, Ishioka et al.
have also demonstrated the utility of including the pan-DR
universalThcellepitope(PADRE)forimprovingvaccination
eﬃcacy [63]. Conversely, Velders et al. did not observe
diﬀerences in inducing antitumor immunity between wild
type and CD4−/− mice vaccinated with a polyepitope DNA
vaccine containing the tetanus-toxoid Th epitope [65]. A
consensus, however, appears to be recognized for the func-
tion of polyepitope organization (epitope rearrangement,6 Journal of Biomedicine and Biotechnology
addition of spacers): it should allow an appropriate cleavage
of all epitopes and should prevent the creation of new
junctional epitopes with high aﬃnity for MHC molecules
[63, 64]. Therefore, the design of a DNA polyepitope vaccine
requires that the arrangement of the epitopes allows the
processing of each peptide at its C-terminal position and
does not create new junctional peptides with high aﬃnity
for MHC. Further, such design should include the selection
of native epitopes or of heteroclytic variants of the epitopes
with high MHC aﬃnity, which should also display high
immunogenicity in vivo and in vitro in preclinical settings.
The deﬁnition of the C-terminal processing position can be
evaluated by using predictive models of proteasome cleavage
[66].
Initial concerns on the use of polyepitope DNA-based
vaccines arose on the possibility that the processing of
multiple epitopes could fail to incorporate them in their
natural context of ﬂanking amino acids residues. It has been
demonstrated that the multicatalytic proteasome complex
anditslowmolecularweightproteinsubunitsareresponsible
for the production of peptides with hydrophobic or basic
C-terminal residues which are preferentially associated with
MHC I molecules [67]. To ﬁt in the grove of most MHC
class I molecules, peptides should possess a length of 8–
10 residues [68]. However, how the ﬁnal peptide length is
attained is not well understood due to conﬂicting evidence
ontheproductionandtransportofantigen-derivedpeptides.
Theproteasomedegradesproteinstopeptidefragmentsof2–
25 residues. While the COOH-terminal residues of peptides
presentedtoMHC-classIaredeterminedbycleavageswithin
the proteasome, the NH2-termini are often generated by
aminopeptidases which trim longer N-extended proteasome
products to mature peptides [68]. Some authors have
suggested that peptides of suboptimal length in respect
to MHC-binding could be produced when they are more
eﬃciently translocated into the endoplasmic reticulum (ER)
by the TAP molecules. These peptides are then trimmed in
the ER before association with class I molecules [69]. Indeed,
endoplasmatic reticulum aminopeptidase 1 (ERAP1), an
IFN-γ-induced aminopeptidase, trims long precursors to the
mature peptides presented on MHC class I [68]. ERAP1
prefers peptides of 9–16 residues and seems to lose activity
when are generated epitopes 8 or 9 residues long [68]. The
activityofERAP1dependsontheCOOH-terminiofthesub-
strate, the enzyme having a high aﬃnity for large hydropho-
bic COOH-terminal residues. This preferential aﬃnity has
immunological implications: since human TAP shows aﬃn-
ityforbasicaswellashydrophobicCOOH-terminalresidues,
epitopes with basic COOH-terminal residues are most likely
produced independently of ERAP1 [68]. Indeed, diﬀerent
authorsreportthatTAPmoleculesthemselvesselectpeptides
of optimal length for MHC association, which are produced
solelybycytosolicendopeptidases[70].Themoleculardeter-
minants of peptide cleavage indicate that diﬀerent stages of
the antigen processing pathway are likely to be important in
the successful presentation of polyepitope. For example, if a
particular epitope requires a cleavage at a speciﬁc point, a
number of residues upstream of its N-terminus, which are
necessaryforeﬃcienttranslocation,willneedtoberemoved.
However, this process could have a deleterious eﬀect on the
processing of immediately adjacent epitopes which can be
internally cleaved. For this reason, several constructs have
been made by inserting alanine spacers between residues
to provide peptidase cleavage points outside the epitope
sequence [71].
Del Val et al. demonstrated that not only the sequence
of the presented peptide but also that of its ﬂanking residues
determine the eﬃciency of processing and presentation and
that a low yield of antigenic peptide due to an unfavorable
integration site could be overcome by ﬂanking the insert
with oligo-alanine to space it from disruptive neighboring
sequences [72]. This result indicated the need to include
particular ﬂanking residues in the construct in order to
obtain a correct peptide cleavage and processing. Conversely,
Thompson et al. found that a construct incorporating
directly-linked Epstein-Barr virus epitopes with no ﬂanking
sequences was capable as well of inducing CTL recognition
of all its epitopes when delivered to cells by vaccinia virus
[73].
4.Polyepitope DNA-Based CancerVaccines:
Results of PreclinicalIn Vivoand
In Vitro Studies
Polyepitope DNA-based cancer vaccines have demonstrated
promising results in preclinical studies.
Results of these studies are described below. Qin et al.
selected and ligated together several DNA fragments encod-
ing multiple CTL and Th cell epitopes from human prostate-
speciﬁc membrane antigen (hPSM), mouse prostatic acid
phosphatase (mPAP), and human prostate-speciﬁc antigen
(hPSA). It was thus formed a novel fusion gene, termed 3P
gene, which was inserted into a plasmid DNA along with a
gene encoding for the human IgG Fc to construct a DNA
vaccine. Vaccination with this polyepitope DNA induced a
strong antitumor response in a mouse tumor model, signif-
icantly inhibited tumor growth and prolonged survival time
of the tumor-bearing mice. CTLs were also induced which
could speciﬁcally kill hPSM-, hPAP-, or hPSA-expressing
tumor cells [74]. The authors then formulated a novel
chemotactic antigen DNA vaccine encoding chemokines
and multiepitopes of prostate-TAA. This vaccine enhanced
antitumorimmunity.Inaddition,whenhumanlymphocytes
were stimulated by autologous PBMCs transfected with the
plasmid DNA vaccine, CTLs were induced which could
kill hPSM-, hPAP-, or hPSA-expressing tumor cells [75].
The utility to insert a chemokine in the polyepitope DNA
vaccine was also demonstrated by Sun et al., who showed
that the immunization of mice with a fused-gene DNA
vaccine containing the N-terminus of both MHC class I-
restricted and class II-restricted T-cell epitopes from HER-
2/neu and p53 linked to the sequence encoding for human
secondary lymphoid-tissue chemokine, and the C-terminus
linked to a cell-binding domain of IgG, reduced the size
of established tumours, prolonged the lifespan of tumour-
bearing mice, and enhanced the antigen-speciﬁc cellular and
humoral immune responses [76].Journal of Biomedicine and Biotechnology 7
The usefulness to insert a Th epitope or an adjuvant
mimic gene was reproducibly reported. Zhang et al. linked
the full-length human prostate stem-cell antigen (PSCA)
gene to the N- or C-terminus of human heat shock protein
HSP70 as adjuvant and investigated whether HSP70 could
enhance the potency of the DNA vaccines. Mice vacci-
nated with PSCA-HSP plasmids generated a strong PSCA-
speciﬁc CD8+ T-cell immune response [77]. Similarly, it was
demonstrated that a DNApoly1 vaccine encoding a protein
containing an ER (Ig jchain) signal sequence, the PADRE
Th epitope, and a number of HPV CTL epitopes elicited
powerful eﬀector CTL responses and long-lived memory
CTL responses in immunized mice [78]. In addition, it was
proven that the combination of the gene which encodes
a protein, called the class II MHC transactivator, (CIITA)
with calreticulin/E6 and Ii-PADRE (pan HLA-DR-reactive
epitope) DNA vaccines represents a potentially eﬀective
cancer vaccine, because of the ability of the vaccine to
increase the levels of MHC class I/II molecules and lead
to enhanced presentation of the antigen via the MHC class
I and II processing pathways [79]. On the other hand,
the advantage of removing the second domain of fragment
C (FrC) of tetanus toxin Th was demonstrated, because
of potentially containing competitive epitopes which were
able to depress induction of CEA-speciﬁc CTLs [80]. The
injection of DNA encoding HPV E6 or E7 antigen with
DNA encoding Ii-PADRE led to signiﬁcantly stronger E6-
or E7-speciﬁc CD8+ T-cell immune responses and more
potent protective and therapeutic antitumor eﬀects against
an E6/E7-expressing tumor model in mice as compared to
the administration of E6 or E7 DNA with Ii DNA, thus indi-
cating that administration of DNA vaccines with Ii-PADRE
D N Ai sa ne ﬀective tool to elicit stronger antigen-speciﬁc
CD8+ T-cell immune responses [81]. Immunogenicity of
cryptic epitopes delivered by a multiepitopes DNA-based
vaccine was also demonstrated. In this respect, Scardino
et al. designed a cDNA vaccine encoding 12 diﬀerent
HER-2/ErbB-2-derived, including HLA-A
∗0201-restricted,
dominant and high-aﬃnity heteroclitic cryptic epitopes.
Vaccination of HLA-A
∗0201 transgenic HHD mice with
this ErbB2 multiepitopes vaccine triggered multiple ErbB-
2-speciﬁc CTL responses in vitro and signiﬁcantly delayed
the growth of challenged ErbB-2-expressing tumors in vivo.
In addition, a T cells multiple response from HLA-A
∗0201
healthy donors was obtained in vitro upon stimulation of
dendritic cells with the multiepitopes vaccine [82].
However, a biased T cells response upon a multiepitopes
DNA-based vaccine was also showed. This event might be
due to the presence of an immunodominant epitope within
subdominant epitopes in the vaccine. Indeed, it was proven
that a single immunization with a DNA plasmid minigene
construct encoding four human leucocyte antigen (HLA)-
A2-restricted epitopes belonging to tumour antigens CEA,
MAGE2 and MAGE3, as well as the universal PADRE epitope
recognized by Th lymphocytes, induced a monospeciﬁc
immune response only against the immunodominant CEA
epitope [83]. Polyepitope design and constructions should
takeintoaccounttherespectivepositionofsubdominantand
dominant epitopes, in order to trigger an eﬃcient and broad
T cell epitope response. Yet, results obtained after HDD mice
vaccination with an HER-2 multiepitopic DNA construct
containing heteroclytic cryptic epitopes within native and
immunodominant epitopes did not show any prevalent
immunodominanceamongdiﬀerentepitopes,althoughCTL
activity on target cells bearing certain HER-2 peptides was
variable. In addition, stimulation of human PBMCs from
diﬀerent donors with the polyepitope DNA vaccine showed
evidence of CTL response variability among individuals,
demonstrating the possibility to mobilize human T cell
repertoires speciﬁc for multiple HER-2 epitopes including
cryptic epitopes. The multiple epitopes-induced CTLs were
capable to kill MCF-7 tumor cells in vitro [82]. Conversely,
Smith et al. provided in vitro evidence that a melanoma
polyepitope cDNA vaccine was able stimulate lymphocytes
from normal human donors to simultaneously generate
multiple antigen-speciﬁc responses [84]. Interestingly, the
use of multiepitopes DNA vaccines delivered by dendritic
cells(DC)wasalsoinvestigated.DCstransfectedwithhuman
telomerase reverse transcriptase (hTERT)-IL18 gene were
capable of eliciting a stronger hTERT-speciﬁc CTL response
in vitro than that stimulated with the hTERT construct only
[85]. In addition, an eﬃcient induction of tumor antigen-
speciﬁc immune response in vitro by DCs pulsed with a
recombinant fusion protein of Hsp70 and CEA(576–669), a
fragment of the carcinoembryonic antigen (CEA) containing
CAP-1, was reported [86].
5.Polyepitope DNA-Based CancerVaccine:
Results of ClinicalTrialsandFuture
Perspectives
The use of DNA-based cancer vaccines appears a novel tool
for eﬃcient activation of diverse T cell immune responses
against cancer. However, the promising data obtained in
preclinicalmodelswerenotimmediatelyfollowedbyencour-
aging results in cancer patients. In fact, early clinical trials
employing DNA-based vaccines showed a limited immunity
to the delivered TAA. For example, Rosenberg et al. were
unable to demonstrate signiﬁcant clinical or immunological
responses to the administration of a plasmid DNA encoding
the “self-” nonmutated gp100 tumor antigen in 22 patients
with metastatic melanoma. Only one patient exhibited a
partial response of several subcentimeter cutaneous nodules
[87]. Similarly, Triozzi et al. demonstrated that although the
injection of a plasmid containing MART-1 was safe when
administered to 12 patients with resected melanoma at risk
forrelapse,nopatientmanifestedincreasedMART-1-speciﬁc
lymphoproliferative responses [88].
Conversely, evidence of both immune and clinical
responses in the same patients was observed in prostate
cancer patients administered with a DNA vaccine encoding
prostate-speciﬁc antigen [89, 90]. A multiepitopes-DNA-
based vaccine was employed by Tagawa et al. who vaccinated
stage IV melanoma patients with a recombinant plasmid
DNA vaccine encoding two peptides derived from human
tyrosinase, that is tyrosinase 207–216 and tyrosinase 1–
17. The authors reported that immune responses were8 Journal of Biomedicine and Biotechnology
detected in 11 of 26 patients. No clinical responses were
seen. Still, survival of the heavily pretreated patients on
this trial was unexpectedly long, with 16 of 26 patients
alive at a median follow-up of 12 months [91]. Klencke
et al. observed that 10 of 12 eligible subjects with HPV-
16 anal infection and a HLA-A2 haplotype responded to
the vaccination with a plasmid DNA encoding for multiple
HLA-A2-restricted epitopes derived from the HPV-16 E7
protein. In addition, 3 patients obtained a partial histological
response [92]. Conversely, Smith et al. produced no direct
evidence that 2 injections of a plasmid DNA encoding
7 melanoma tumor antigen CTL epitopes were capable
of priming an immune response against the recombinant
gene products when administered in HLA-A
∗0201-positive
patients with surgically treated melanoma [93]. According
to these trials it appears that the immune responses elicited
by TAA polyepitope DNA vaccines in cancer patients are
weaker than those induced by other forms of recombinant
vaccines.
TAA polyepitope DNA vaccines aim at inducing TAA
speciﬁc CTLs. However, accumulating evidence shows that
tumor cells can escape immune destruction [94]. In
this regard the tumor microenvironment plays a pivotal
role in determining the fate of the emerging anti-cancer
immune response [3, 94, 95]. Solid tumors are composed
of cancer cells embedded in a variety of non-malignant
cells (macrophages, lymphocytes, vascular cells, ﬁbroblasts)
which form the tumor stroma [94, 95]. Beside the alteration
in antigen processation and presentation, cancer cells and
tumor stromal cells can produce local immunosuppressive
factors [94]. Cancer cells can also become resistant to CTL-
mediated cytotoxic pathways, for instance acquiring resis-
tance to perforins and granzyme B or through the alteration
of death receptors expression or signaling [94]. In addition,
cancercellgeneticinstabilitycanleadtothealterationofpro-
apoptotic regulators, one of the most important being p53.
It has been demonstrated that the p53 status of cancer cells
has a key role in determining the fate of the anti-tumor CTL
response since it regulates Fas receptor expression, cellular
FLICE/caspase-8 inhibitory protein (cFLIP) short protein
degradation,andCD95-mediatedapoptosis[94].Cancercell
cytoskeletondisorganizationcanconferresistancetoCTLsas
well [94].
The limited anti-tumor and clinical responses obtained
with TAA polyepitope DNA-based vaccines might be due
also to the poor immunogenicity of plasmid DNA itself, in
particularwhentheplasmidDNAisusedaloneanddelivered
through needle injection [56]. Indeed, one issue related to
the low immunogenicity of DNA vaccine is represented by
ineﬃcient plasmid DNA uptake following either skin or
muscle injection [54]. In addition, the eﬀectiveness of in
vivo DNA transfection attained in murine models might
not correctly be converted into proper dosage for humans
[56]. Diﬀerent techniques can be employed to enhance DNA
uptake and immunogenicity, including gene gun delivery
and electroporation. Besides, CpG neutralizing sequences
present within the plasmid DNA backbone can inhibit the
activation of DNA uptake by APCs [54]. In this respect, it
would be of help to choose CpG sequences which allow the
maturation of selected immune cell types, while replacing
CpG inhibitory motifs [56].
DuetothelowimmunogenicityofplasmidDNA,eﬃcacy
in priming the immune response is often below detection
levelsattheendoftheimmunizationprotocol,butitemerges
after the host is boosted with a diﬀerent form of vaccine
deliveringthesameantigen[96].Itisclearthatantigencross-
presentation from skin or muscle cells to antigen-presenting
cells(APCs)isthemajorrouteforimmuneresponsepriming
[60]. However, a long lasting immune response is obtained
through a two step-process, that is, priming and boost.
While priming of immune cells requires a low dose of
antigen, the boost needs a larger amount of antigen [96].
The immunogenicity of DNA vaccines could be enhanced
by increasing the administered dose, although the cost of
usinghighamountsofplasmidDNAwillmakethisapproach
economically unaﬀordable [96]. Thus, it is likely that DNA
vaccines could eﬃciently induce cell-mediated immunity
mainly via priming of dendritic cells in vivo. The adjuvant
nature of bacterial DNA plasmids used as delivery vectors
also furnishes a potent immunostimulatory eﬀect for the
Th1 phenotype and can promote CTL-induction even in the
absence of speciﬁc helper.
Finally,polyepitopeDNAconstructsshouldbeoptimized
before clinical usage. All modiﬁcations and every combina-
tion of epitopes require previous validations by experimental
prediction (motif sampler, weight matrix, and artiﬁcial
neural network) [97] and in vitro preclinical studies. In fact,
future studies should be focused on the development of
strategiestoenhanceepitopeexpression,toimproveimmune
recruitment, and to select the best combination of epitopes
which can drive a strong T cell response toward a TAA/s.
Future studies should be focused on the development of
strategiestoenhanceepitopeexpression,toimproveimmune
recruitment and to select the best combination of epitopes
which can drive a strong T cell response toward a TAA/s. In
addition, a better understanding of the proteasome/TAP/ER-
mediated processing of polyepitope proteins will allow the
design of DNA constructs optimized for eﬃcient presenta-
tion of all incorporated epitopes. Undoubtedly, a key feature
for the use of polyepitope DNA-based cancer vaccines is
their extraordinary feasibility, which in the future may allow
to design speciﬁc DNA vaccines tailored on the MHC/TAA
epitopes proﬁle peculiar for each patient.
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